30 closest matches · ranked by relevance
Focus of the Study:Protein Binding Characteristics of Voriconazole.
Primary: Differences in Overall Protein Binding in the Presence of Different Plasma Albumin Concentrations. — 49.1; 49.6 % of plasma protein binding
Healthy
Primary: Steady-State Cmax and Cmin of Two Voriconazole Dosing Regimens — 2.36; 4.16; 0.81; 1.76 mg/L
Leukemia · Fungal Infection
Primary: Percentage of Samples With BG Levels > 60pg/ml — 4; 5; 3; 3 percent of blood samples
Aspergillus Infections · Candida Infections · Fungal Infections
Primary: Cmax of Voriconazole — 2433.7; 1997.0 ng/mL
Pharmacokinetics
Primary: Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration — 22.39 μg*h/mL
Human Immunodeficiency Virus Type 1 (HIV-1) · HIV Infections
Primary: Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Cmin) of Atazanavir, Administered as Atazanavir/Ritonavir With and Without…
Aspergillosis, Aspergilloma
Primary: Area Under the Plasma Concentration-time Profile From Time Zero to Twelve Hours at Steady-State (AUC12,ss) Following IV Administration — 51.92; 83.39; 17.27 μg*h/mL
Fungal Infection
Primary: Number of Participants With Treatment Failure — 1; 5 participants
Infections, Fungal
Primary: Plasma Concentrations of Voriconazole — 839.50; 2182.33 ng/mL
Candidiasis · Candidemia
Primary: Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration — 21.42 μg*h/mL
Invasive Fungal Infections
Primary: Number of Participants With Clinical and/or Mycological Efficacy by Response at the End of Treatment (EOT) Visit — 64; 64; 36; 34 participants
Allergic Bronchopulmonary Aspergillosis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAE) — 0; 3; 2; 2 participants
Systemic Fungal Infections
Primary: Posaconazole Exposure Described as Area Under the Total Plasma Concentration-time Curve From Time Zero to Infinity After a Single Dose — 17932 ng*h/mL
Aspergillosis · Candidemia
Primary: Plasma Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) — 6.56; 5.32 ug/mL
Healthy
Primary: Area Under the Concentration-time Curve of BI 113608 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 494; 1840; 1320…
Fungal Keratitis
Primary: Best Spectacle Corrected Visual Acuity (BSCVA) 3 Months After Enrollment, Adjusting for Enrollment BSCVA in a Multiple Linear Regression Model — 0.61; 0.71 logMAR — p=0.29
Scedosporium Infection
Primary: Number of Participants With Serious Treatment Related Adverse Events. — 2 participants
Serious Fungal Infections
Primary: Percentage of Participants With Categorical Clinical Response: Cure, Improvement, Failure, or Unevaluable — 12.72; 41.47; 17.92; 27.89 percentage of participants
Non-Melanoma Skin Carcinoma
Primary: Number of Participants Who Developed Non-Melanoma Skin Cancer (NMSC) — 34; 23 participants — p=0.042
Systemic Mycosis
Primary: Number of Participants With the Frequency of Treatment Related Adverse Events. — 220 participants
Lymphoma · Infection · Leukemia
Primary: Fungal-free Survival (Percentage of Participants Alive and Free From Proven, Probable, or Presumptive Invasive Fungal Infection) at 180 Days Post-transplant — 74.9; 78.2…
Corneal Ulcer · Eye Infections, Fungal
Primary: Incidence of Perforation or Therapeutic Penetrating Keratoplasty — 0.0095562; 0.011204 New perforations or TPK/person-days — p=0.29
Fungal Infection
Primary: Number of Participants With Adverse Drug Reactions — 62; 5 Participants
Fungal Infections · Invasive Pulmonary Aspergillosis
Primary: Percentage of Participants Who Died Through Day 42 in the Intention to Treat Population — 15.3; 20.6 Percentage of Participants — p=<.0001
Leukemia · Fungal Infection
Primary: Maximum Observed Concentration in Plasma (Cmax) — 200; 290; 300; 580 ng/ml
Serious Fungal Infections
Primary: Percentage of Participants With Categorical Clinical Response: Cure, Improvement, Failure, or Unevaluable — 36.83; 26.52; 16.94; 19.71 Percentage of participants
Fungal Infection · Acute Myelogenous Leukemia · Neutropenia
Primary: Mean POS Plasma Concentrations on Days 2, 3, and 8. — 230; 346; 637 ng/mL
Fungal Infection
Primary: Single Dose Trough Concentration of IV Posaconazole (Cmin) — 318; 295; 467 ng/mL
Candidemia
Primary: Serum Cidal Activity as Tested Against Various Candida Isolates and Reported as Ex-vivo Effect (Log Inhibition of Growth) — 3; 0.5; 0; 3 Log inhibition
Febrile Neutropenia
Primary: Mean (SD) Doripenem Pharmacokinetic Volume of Distribution Parameter in Febrile Neutropenic Patients — 36.7; 49.9; 43.9 Liters